Eli Lilly News
-
Novartis AG plans to ramp up its research in Alzheimer’s disease, a potential $20 billion market lacking a major contender and littered with three high-profile drug failures in the past year alone.
-
A cheap regimen of vitamins in use for decades is seen by scientists as a way to delay the start of Alzheimer’s disease and dementia, a goal that prescription drugs have failed to achieve.
-
A hormone treatment based on technology used in Pfizer Inc.’s failed inhalable insulin shows promise in fighting the leading cause of maternal mortality.
-
Teva Pharmaceutical Industries Ltd., which just two years ago was analysts’ highest-rated stock among the world’s 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.
-
Updated 3 hours, 17 minutes ago
H. Lundbeck A/S, Denmark’s second- largest drugmaker, said its experimental antidepressant Brintellix improved symptoms better in a higher dose in a late- stage U.S. study, as the medicine awaits regulatory approval.
-
Canada’s Supreme Court dismissed Eli Lilly & Co.’s request to appeal a federal court decision that invalidated its Canadian patent for schizophrenia drug Zyprexa.
-
Canada’s Supreme Court dismissed Eli Lilly & Co.’s request to appeal a federal court decision that invalidated its Canadian patent for schizophrenia drug Zyprexa.
-
Eli Lilly & Co. Chief Executive Officer John Lechleiter underwent a scheduled surgery yesterday for a heart defect and the repair to the aorta is functioning as intended, the drugmaker said.
-
Angelina Jolie, named the highest- paid actress in Hollywood by Forbes in 2011, said she had a double mastectomy after learning she has a gene mutation linked to breast cancer, the disease that killed her mother at age 56.
-
Angelina Jolie’s decision to have a double mastectomy is fueling debate among the thousands of women at risk of developing breast cancer who want to know how, if and when to have their breasts removed.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page